Imagen de Portada

The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Naja Nyffenegger, Anna Flace, Ahmet Varol, Patrick Altermatt, Cédric Doucerain, Hanna Sundstrom, Franz Dürrenberger, Vania Manolova
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	HemaSphere
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Interferon gamma‐mediated prevention of tumor progression in a mouse model of multiple myeloma
por: Zoltán Kellermayer, et al.
Publicado: (2024)

Waiting and seeing: The importance of long‐term system‐wide monitoring of mouse models of disease
por: David G. Kent
Publicado: (2025)

Fibrinogen‐like 1: A hepatokine linking liver physiology to hematology
por: Jean Personnaz, et al.
Publicado: (2024)

Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors
por: Romain Stammler, et al.
Publicado: (2025)

Liver iron concentration thresholds: Where do they really come from?
por: Lukas Müller, et al.
Publicado: (2025)

Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia‐positive lymphoid leukemia to tyrosine kinase inhibitors
por: Lukasz Komorowski, et al.
Publicado: (2024)

Additive effect of multiple genetic variants in SEC23B and PIEZO1 on iron metabolism dyshomeostasis in hereditary anemias
por: Antonella Nostroso, et al.
Publicado: (2026)

The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
por: Andrew D. Zelenetz, et al.
Publicado: (2024)

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience
por: Idanna Innocenti, et al.
Publicado: (2024)

Combination of targeted pharmacotherapy and immunotherapy with anti‐CD19 CAR NK cells in acute lymphoblastic leukemia
por: Hanna Kirchhoff, et al.
Publicado: (2025)

Implementation science in hemato‐oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM)
por: Jean‐Michel Cayuela, et al.
Publicado: (2025)

Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group
por: Pierre Sesques, et al.
Publicado: (2026)

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL
por: Sarka Pavlova, et al.
Publicado: (2025)

Issue Information
Publicado: (2025)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
por: Raúl Córdoba, et al.
Publicado: (2026)

Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition
por: Anna Ossami Saidy, et al.
Publicado: (2025)

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
por: Enrico Attardi, et al.
Publicado: (2024)

Cell‐free DNA for detection and monitoring of extramedullary AML relapse
por: Henri C. Hupe, et al.
Publicado: (2025)

Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
por: Jan‐Niklas Eckardt, et al.
Publicado: (2025)

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction
por: Konstanze Döhner, et al.
Publicado: (2025)

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
por: David A. Sallman, et al.
Publicado: (2025)

TET3 regulates hematopoietic stem cell homeostasis during embryonic and adult hematopoiesis
por: Harmony C. Ketchum, et al.
Publicado: (2025)

Dynamics of BCR::ABL1 transcript levels and clinical outcomes after switch to second‐line therapy in pediatric chronic myeloid leukemia
por: Stephanie Sembill, et al.
Publicado: (2026)

Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
por: Uwe Platzbecker, et al.
Publicado: (2025)

HELIOS Action: Advancing research, education, and equity in hemoglobinopathies across Europe and beyond
por: Sotiroula Chatzimatthaiou, et al.
Publicado: (2025)

MMS22L is a novel key actor of normal and pathological erythropoiesis
por: Elia Colin, et al.
Publicado: (2025)

Correction to “Quality of vitamin K antagonist treatment during the last year of life”
Publicado: (2025)

Should the current diagnostic criteria for CLL be reconsidered? A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
por: Daniel Mazza Matos
Publicado: (2026)

Publication Only
Publicado: (2025)

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
por: Cristina A. Tentori, et al.
Publicado: (2024)

Mutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
por: Rebeqa Gunnarsson, et al.
Publicado: (2025)

Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
por: Mwanasha H. Merrill, et al.
Publicado: (2025)

Patterns of immune recovery after axicabtagene ciloleucel for aggressive B‐cell lymphoma
por: André Airosa Pardal, et al.
Publicado: (2025)

Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study
por: Martijn W. C. Verbeek, et al.
Publicado: (2025)

Unraveling the role of TP53 mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation
por: Suzana da Silva‐Benedito, et al.
Publicado: (2026)

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma
por: Thomas C. Wiemers, et al.
Publicado: (2026)

Dynamic evolution of TCF3‐PBX1 leukemias at the single‐cell level under chemotherapy pressure
por: Mira Kusterer, et al.
Publicado: (2025)

Correction to “Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network”
Publicado: (2025)

Issue Information
Publicado: (2024)

APL‐like subset within NPM1 ‐mutated AML: A distinct immunophenotype correlating with early vascular complications
por: Francesco Mannelli, et al.
Publicado: (2026)